Literature DB >> 15262907

Effects of local administrations of tempol and diethyldithio-carbamic on peripheral nerve activity.

Takatomi Shokoji1, Yoshihide Fujisawa, Shoji Kimura, Matlubur Rahman, Hideyasu Kiyomoto, Keisuke Matsubara, Kumiko Moriwaki, Yasuharu Aki, Akira Miyatake, Masakazu Kohno, Youichi Abe, Akira Nishiyama.   

Abstract

We have recently shown that systemic administration of a superoxide dismutase mimetic, tempol, resulted in decreases in mean arterial pressure and heart rate along with a reduction in renal sympathetic nerve activity (RSNA). It has also been shown that these parameters are significantly increased by systemic administration of a superoxide dismutase inhibitor, diethyldithio-carbamic (DETC), indicating a potential role of reactive oxygen species in the regulation of RSNA. In this study, we examined the effects of local administrations of 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (tempol) and DETC on RSNA in anesthetized rats. Either tempol or DETC was directly administered onto the renal sympathetic nerves located between the electrode and ganglion. Local application of tempol (10 microL, 0.17 to 1.7 mol/L, n=6) resulted in dose-dependent decreases in integrated RSNA (by -81+/-6% at 1.7 mol/L) without alterations in mean arterial pressure and heart rate. In contrast, DETC (10 microL, 0.17 to 1.7 mol/L, n=6) increased RSNA dose-dependently. The responses of RSNA to tempol and DETC were significantly greater in spontaneously hypertensive rats than in normotensive rats (n=6, respectively). Local application of sodium nitroprusside (1 mmol/L) or N(G)-nitro-L-arginine methyl ester (0.11 mol/L) altered neither basal RSNA nor tempol-induced reductions in RSNA (n=6 and 5, respectively). A voltage-gated potassium channel blocker, 4-aminopyridine (0.1 mol/L), significantly decreased basal RSNA (by -81+/-1%) and completely prevented DETC-induced increases in RSNA (n=5). These results suggest that reactive oxygen species play a role in the regulation of peripheral sympathetic nerve activity, and that at least part of this mechanism is mediated through voltage-gated potassium channels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262907     DOI: 10.1161/01.HYP.0000136393.26777.63

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Oxidative stress and the muscle reflex in heart failure.

Authors:  Satoshi Koba; Zhaohui Gao; Lawrence I Sinoway
Journal:  J Physiol       Date:  2009-09-01       Impact factor: 5.182

2.  Endothelin activation of reactive oxygen species mediates stress-induced pressor response in Dahl salt-sensitive prehypertensive rats.

Authors:  Gerard D'Angelo; Analia S Loria; David M Pollock; Jennifer S Pollock
Journal:  Hypertension       Date:  2010-06-14       Impact factor: 10.190

Review 3.  Chemistry and antihypertensive effects of tempol and other nitroxides.

Authors:  Christopher S Wilcox; Adam Pearlman
Journal:  Pharmacol Rev       Date:  2008-12       Impact factor: 25.468

4.  Systemically administered tempol reduces neuronal activity in paraventricular nucleus of hypothalamus and rostral ventrolateral medulla in rats.

Authors:  Shun-Guang Wei; Zhi-Hua Zhang; Yang Yu; Robert B Felder
Journal:  J Hypertens       Date:  2009-03       Impact factor: 4.844

Review 5.  Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors.

Authors:  Mouhamed Nashawi; Omar Sheikh; Ayman Battisha; Abdullah Ghali; Robert Chilton
Journal:  Heart Fail Rev       Date:  2020-11-09       Impact factor: 4.214

6.  Sympathetic regulation of vascular function in health and disease.

Authors:  Rosa M Bruno; Lorenzo Ghiadoni; Gino Seravalle; Raffaella Dell'oro; Stefano Taddei; Guido Grassi
Journal:  Front Physiol       Date:  2012-07-24       Impact factor: 4.566

7.  Systemic Administration of Tempol, a Superoxide Dismutase Mimetic, Augments Upper Airway Muscle Activity in Obese Zucker Rats.

Authors:  Santhosh M Baby; Lisa H Tanner; Joseph F Discala; Ryan B Gruber; Yee-Hsee Hsieh; Stephen J Lewis
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.